139 related articles for article (PubMed ID: 17569106)
21. DR5 and DcR2 are expressed in human lumbar intervertebral discs.
Chen B; Ma B; Yang S; Xing X; Gu R; Hu Y
Spine (Phila Pa 1976); 2009 Sep; 34(19):E677-81. PubMed ID: 19730199
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.
Arts HJ; de Jong S; Hollema H; ten Hoor K; van der Zee AG; de Vries EG
Gynecol Oncol; 2004 Mar; 92(3):794-800. PubMed ID: 14984943
[TBL] [Abstract][Full Text] [Related]
23. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
24. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
Wagner KW; Punnoose EA; Januario T; Lawrence DA; Pitti RM; Lancaster K; Lee D; von Goetz M; Yee SF; Totpal K; Huw L; Katta V; Cavet G; Hymowitz SG; Amler L; Ashkenazi A
Nat Med; 2007 Sep; 13(9):1070-7. PubMed ID: 17767167
[TBL] [Abstract][Full Text] [Related]
25. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Zhang X; Li W; Olumi AF
Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
[TBL] [Abstract][Full Text] [Related]
26. The expression of TRAIL and its receptors in gastric cancer and the apoptotic effect of rh-TRAIL on SGC7901 cells.
Hu JK; Yang K; Li CM; Zhang B; Chen ZX; Chen XZ; Chen JP
Oncol Rep; 2009 Mar; 21(3):681-8. PubMed ID: 19212626
[TBL] [Abstract][Full Text] [Related]
27. Hydrogen peroxide enhances TRAIL-induced cell death through up-regulation of DR5 in human astrocytic cells.
Kwon D; Choi K; Choi C; Benveniste EN
Biochem Biophys Res Commun; 2008 Aug; 372(4):870-4. PubMed ID: 18534188
[TBL] [Abstract][Full Text] [Related]
28. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
[TBL] [Abstract][Full Text] [Related]
29. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.
Taniguchi H; Yoshida T; Horinaka M; Yasuda T; Goda AE; Konishi M; Wakada M; Kataoka K; Yoshikawa T; Sakai T
Cancer Res; 2008 Nov; 68(21):8918-27. PubMed ID: 18974136
[TBL] [Abstract][Full Text] [Related]
30. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
[TBL] [Abstract][Full Text] [Related]
31. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling.
Ouellet V; Provencher DM; Maugard CM; Le Page C; Ren F; Lussier C; Novak J; Ge B; Hudson TJ; Tonin PN; Mes-Masson AM
Oncogene; 2005 Jul; 24(29):4672-87. PubMed ID: 15940270
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis-related factors (TRAIL, DR4, DR5, DcR1, DcR2, apoptotic cells) and proliferative activity in ameloblastomas.
Rizzardi C; Leocata P; Ventura L; Zweyer M; Brollo A; Schneider M; Melato M
Anticancer Res; 2009 Apr; 29(4):1137-42. PubMed ID: 19414356
[TBL] [Abstract][Full Text] [Related]
33. [Expression of tumor necrosis factor related apoptosis inducing ligand and its receptor in thymus during early post-burn stage in rat with severe burns].
Leng XF; Wang DC; Zhang Q; Feng YQ; Wang K; Xiao H; Huo R; Xue WJ
Zhonghua Shao Shang Za Zhi; 2007 Jun; 23(3):184-7. PubMed ID: 18019056
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
35. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
[TBL] [Abstract][Full Text] [Related]
36. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
[TBL] [Abstract][Full Text] [Related]
37. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
38. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas.
Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Balci MK; Omer A; Griffith TS; Sanlioglu S
Pancreas; 2008 May; 36(4):385-93. PubMed ID: 18437085
[TBL] [Abstract][Full Text] [Related]
39. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
[TBL] [Abstract][Full Text] [Related]
40. Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis.
Li Y; Jin X; Li J; Jin X; Yu J; Sun X; Chu Y; Xu C; Li X; Wang X; Kakehi Y; Wu X
Urology; 2012 Apr; 79(4):968.e7-15. PubMed ID: 22244504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
